Cargando…

Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies

BACKGROUND: Biparametric MRI (bpMRI) is a faster, contrast-free, and less expensive MRI protocol that facilitates the detection of prostate cancer. The aim of this study is to determine whether a biparametric MRI PI-RADS v2.1 score-based model could reduce unnecessary biopsies in patients with suspe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yunhan, Wang, Lei, Tang, Xiaohua, Zhang, Yong, Zhang, Na, Zhi, Biao, Niu, Xiangke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426075/
https://www.ncbi.nlm.nih.gov/pubmed/37582697
http://dx.doi.org/10.1186/s12880-023-01074-7
_version_ 1785089976062443520
author Wang, Yunhan
Wang, Lei
Tang, Xiaohua
Zhang, Yong
Zhang, Na
Zhi, Biao
Niu, Xiangke
author_facet Wang, Yunhan
Wang, Lei
Tang, Xiaohua
Zhang, Yong
Zhang, Na
Zhi, Biao
Niu, Xiangke
author_sort Wang, Yunhan
collection PubMed
description BACKGROUND: Biparametric MRI (bpMRI) is a faster, contrast-free, and less expensive MRI protocol that facilitates the detection of prostate cancer. The aim of this study is to determine whether a biparametric MRI PI-RADS v2.1 score-based model could reduce unnecessary biopsies in patients with suspected prostate cancer (PCa). METHODS: The patients who underwent MRI-guided biopsies and systematic biopsies between January 2020 and January 2022 were retrospectively analyzed. The development cohort used to derive the prediction model consisted of 275 patients. Two validation cohorts included 201 patients and 181 patients from 2 independent institutions. Predictive models based on the bpMRI PI-RADS v2.1 score (bpMRI score) and clinical parameters were used to detect clinically significant prostate cancer (csPCa) and compared by analyzing the area under the curve (AUC) and decision curves. Spearman correlation analysis was utilized to determine the relationship between International Society of Urological Pathology (ISUP) grade and clinical parameters/bpMRI score. RESULTS: Logistic regression models were constructed using data from the development cohort to generate nomograms. By applying the models to the all cohorts, the AUC for csPCa was significantly higher for the bpMRI PI-RADS v2.1 score-based model than for the clinical model in both cohorts (p < 0.001). Considering the test trade-offs, urologists would agree to perform 10 fewer bpMRIs to avoid one unnecessary biopsy, with a risk threshold of 10–20% in practice. Correlation analysis showed a strong correlation between the bpMRI score and ISUP grade. CONCLUSION: A predictive model based on the bpMRI score and clinical parameters significantly improved csPCa risk stratification, and the bpMRI score can be used to determine the aggressiveness of PCa prior to biopsy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12880-023-01074-7.
format Online
Article
Text
id pubmed-10426075
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104260752023-08-16 Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies Wang, Yunhan Wang, Lei Tang, Xiaohua Zhang, Yong Zhang, Na Zhi, Biao Niu, Xiangke BMC Med Imaging Research BACKGROUND: Biparametric MRI (bpMRI) is a faster, contrast-free, and less expensive MRI protocol that facilitates the detection of prostate cancer. The aim of this study is to determine whether a biparametric MRI PI-RADS v2.1 score-based model could reduce unnecessary biopsies in patients with suspected prostate cancer (PCa). METHODS: The patients who underwent MRI-guided biopsies and systematic biopsies between January 2020 and January 2022 were retrospectively analyzed. The development cohort used to derive the prediction model consisted of 275 patients. Two validation cohorts included 201 patients and 181 patients from 2 independent institutions. Predictive models based on the bpMRI PI-RADS v2.1 score (bpMRI score) and clinical parameters were used to detect clinically significant prostate cancer (csPCa) and compared by analyzing the area under the curve (AUC) and decision curves. Spearman correlation analysis was utilized to determine the relationship between International Society of Urological Pathology (ISUP) grade and clinical parameters/bpMRI score. RESULTS: Logistic regression models were constructed using data from the development cohort to generate nomograms. By applying the models to the all cohorts, the AUC for csPCa was significantly higher for the bpMRI PI-RADS v2.1 score-based model than for the clinical model in both cohorts (p < 0.001). Considering the test trade-offs, urologists would agree to perform 10 fewer bpMRIs to avoid one unnecessary biopsy, with a risk threshold of 10–20% in practice. Correlation analysis showed a strong correlation between the bpMRI score and ISUP grade. CONCLUSION: A predictive model based on the bpMRI score and clinical parameters significantly improved csPCa risk stratification, and the bpMRI score can be used to determine the aggressiveness of PCa prior to biopsy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12880-023-01074-7. BioMed Central 2023-08-15 /pmc/articles/PMC10426075/ /pubmed/37582697 http://dx.doi.org/10.1186/s12880-023-01074-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Yunhan
Wang, Lei
Tang, Xiaohua
Zhang, Yong
Zhang, Na
Zhi, Biao
Niu, Xiangke
Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies
title Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies
title_full Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies
title_fullStr Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies
title_full_unstemmed Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies
title_short Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies
title_sort development and validation of a nomogram based on biparametric mri pi-rads v2.1 and clinical parameters to avoid unnecessary prostate biopsies
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426075/
https://www.ncbi.nlm.nih.gov/pubmed/37582697
http://dx.doi.org/10.1186/s12880-023-01074-7
work_keys_str_mv AT wangyunhan developmentandvalidationofanomogrambasedonbiparametricmripiradsv21andclinicalparameterstoavoidunnecessaryprostatebiopsies
AT wanglei developmentandvalidationofanomogrambasedonbiparametricmripiradsv21andclinicalparameterstoavoidunnecessaryprostatebiopsies
AT tangxiaohua developmentandvalidationofanomogrambasedonbiparametricmripiradsv21andclinicalparameterstoavoidunnecessaryprostatebiopsies
AT zhangyong developmentandvalidationofanomogrambasedonbiparametricmripiradsv21andclinicalparameterstoavoidunnecessaryprostatebiopsies
AT zhangna developmentandvalidationofanomogrambasedonbiparametricmripiradsv21andclinicalparameterstoavoidunnecessaryprostatebiopsies
AT zhibiao developmentandvalidationofanomogrambasedonbiparametricmripiradsv21andclinicalparameterstoavoidunnecessaryprostatebiopsies
AT niuxiangke developmentandvalidationofanomogrambasedonbiparametricmripiradsv21andclinicalparameterstoavoidunnecessaryprostatebiopsies